[1]
Becker, S.; Groner, B.; Müller, C.W. Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature, 1998, 394(6689), 145-151. [http://dx.doi.org/10.1038/28101]. [PMID: 9671298].
[2]
Ihle, J.N. STATs: Signal transducers and activators of transcription. Cell, 1996, 84(3), 331-334. [http://dx.doi.org/10.1016/S0092-8674(00)81277-5]. [PMID: 8608586].
[3]
Darnell, J.E. STATs and gene regulation. Science, 1997, 277(5332), 1630-1635. [http://dx.doi.org/10.1126/science.277.5332.1630]. [PMID: 9287210].
[4]
Rawlings, J.S.; Rosler, K.M.; Harrison, D.A. The JAK/STAT signaling pathway. J. Cell Sci., 2004, 117(Pt 8), 1281-1283. [http://dx.doi.org/10.1242/jcs.00963]. [PMID: 15020666].
[5]
Chowdhury, F.Z.; Farrar, J.D. STAT2: A shape-shifting anti-viral super STAT. JAK-STAT, 2013, 2(1), e23633. [http://dx.doi.org/10.4161/jkst.23633]. [PMID: 24058798].
[6]
Horvath, C.M. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem. Sci., 2000, 25(10), 496-502. [http://dx.doi.org/10.1016/S0968-0004(00)01624-8]. [PMID: 11050435].
[7]
Xiong, A.; Yang, Z.; Shen, Y.; Zhou, J.; Shen, Q. Transcription Factor STAT3 as a novel molecular target for cancer prevention. Cancers (Basel), 2014, 6(2), 926-957. [http://dx.doi.org/10.3390/cancers6020926]. [PMID: 24743778].
[8]
Fagard, R.; Metelev, V.; Souissi, I.; Baran-Marszak, F. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAK-STAT, 2013, 2(1), e22882. [http://dx.doi.org/10.4161/jkst.22882]. [PMID: 24058788].
[9]
O’Shea, J.J.; Schwartz, D.M.; Villarino, A.V.; Gadina, M.; McInnes, I.B.; Laurence, A. The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu. Rev. Med., 2015, 66(1), 311-328. [http://dx.doi.org/10.1146/annurev-med-051113-024537]. [PMID: 25587654].
[10]
Liongue, C.; Sertori, R.; Ward, A.C. Evolution of cytokine receptor signaling. J. Immunol., 2016, 197(1), 11-18. [http://dx.doi.org/10.4049/jimmunol.1600372]. [PMID: 27317733].
[11]
Yu, H.; Jove, R. The STATs of cancer--new molecular targets come of age. Nat. Rev. Cancer, 2004, 4(2), 97-105. [http://dx.doi.org/10.1038/nrc1275]. [PMID: 14964307].
[12]
Haura, E.B.; Turkson, J.; Jove, R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol., 2005, 2(6), 315-324. [http://dx.doi.org/10.1038/ncponc0195]. [PMID: 16264989].
[13]
Gao, Y.; Zhao, H.; Wang, P.; Wang, J.; Zou, L. The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases. Scand. J. Immunol., 2018, 88(6), e12727. [http://dx.doi.org/10.1111/sji.12727]. [PMID: 30341772].
[14]
Groner, B.; von Manstein, V. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Mol. Cell. Endocrinol., 2017, 451, 1-14. [http://dx.doi.org/10.1016/j.mce.2017.05.033]. [PMID: 28576744].
[15]
Wang, Y.; Shen, Y.; Wang, S.; Shen, Q.; Zhou, X. The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett., 2018, 415, 117-128. [http://dx.doi.org/10.1016/j.canlet.2017.12.003]. [PMID: 29222039].
[16]
Hirano, T.; Ishihara, K.; Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene, 2000, 19(21), 2548-2556. [http://dx.doi.org/10.1038/sj.onc.1203551]. [PMID: 10851053].
[17]
Heinrich, P.C.; Behrmann, I.; Müller-Newen, G.; Schaper, F.; Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J., 1998, 334(Pt 2), 297-314. [http://dx.doi.org/10.1042/bj3340297]. [PMID: 9716487].
[18]
Aigner, P.; Just, V.; Stoiber, D. STAT3 isoforms: Alternative fates in cancer? Cytokine, 2019, 118, 27-34. [PMID: 30031681].
[19]
Schaefer, T.S.; Sanders, L.K.; Nathans, D. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc. Natl. Acad. Sci. USA, 1995, 92(20), 9097-9101. [http://dx.doi.org/10.1073/pnas.92.20.9097]. [PMID: 7568080].
[20]
Shao, H.; Quintero, A.J.; Tweardy, D.J. Identification and characterization of cis elements in the STAT3 gene regulating STAT3 alpha and STAT3 beta messenger RNA splicing. Blood, 2001, 98(13), 3853-3856. [http://dx.doi.org/10.1182/blood.V98.13.3853]. [PMID: 11739197].
[21]
Zhang, Y.; Wang, D.; Xu, J.; Wang, Y.; Ma, F.; Li, Z.; Liu, N. Stat3 activation is critical for pluripotency maintenance. J. Cell. Physiol., 2019, 234(2), 1044-1051. [http://dx.doi.org/10.1002/jcp.27241]. [PMID: 30256396].
[22]
Huang, G.; Yan, H.; Ye, S.; Tong, C.; Ying, Q.L. STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates mouse ESC fates. Stem Cells, 2014, 32(5), 1149-1160. [http://dx.doi.org/10.1002/stem.1609]. [PMID: 24302476].
[23]
Hazan-Halevy, I.; Harris, D.; Liu, Z.; Liu, J.; Li, P.; Chen, X.; Shanker, S.; Ferrajoli, A.; Keating, M.J.; Estrov, Z. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood, 2010, 115(14), 2852-2863. [http://dx.doi.org/10.1182/blood-2009-10-230060]. [PMID: 20154216].
[24]
Shi, X.; Zhang, H.; Paddon, H.; Lee, G.; Cao, X.; Pelech, S. Phosphorylation of STAT3 serine-727 by cyclin-dependent kinase 1 is critical for nocodazole-induced mitotic arrest. Biochemistry, 2006, 45(18), 5857-5867. [http://dx.doi.org/10.1021/bi052490j]. [PMID: 16669628].
[25]
Qin, H.R.; Kim, H.J.; Kim, J.Y.; Hurt, E.M.; Klarmann, G.J.; Kawasaki, B.T.; Duhagon Serrat, M.A.; Farrar, W.L. Activation of Stat3 through a Phosphomimetic Serine727 promotes prostate tumorigenesis independent of tyrosine705 phosphorylation. Cancer Res., 2008, 68(19), 7736-7741. [http://dx.doi.org/10.1158/0008-5472.CAN-08-1125]. [PMID: 18829527].
[26]
Hendry, L.; John, S. Regulation of STAT signalling by proteolytic processing. Eur. J. Biochem., 2004, 271(23-24), 4613-4620. [http://dx.doi.org/10.1111/j.1432-1033.2004.04424.x]. [PMID: 15606748].
[27]
Hevehan, D.L.; Miller, W.M.; Papoutsakis, E.T. Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood, 2002, 99(5), 1627-1637. [http://dx.doi.org/10.1182/blood.V99.5.1627]. [PMID: 11861277].
[28]
Caldenhoven, E.; van Dijk, T.B.; Solari, R.; Armstrong, J.; Raaijmakers, J.A.; Lammers, J.W.; Koenderman, L.; de Groot, R.P. STAT3β, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem., 1996, 271(22), 13221-13227. [http://dx.doi.org/10.1074/jbc.271.22.13221]. [PMID: 8675499].
[29]
Maritano, D.; Sugrue, M.L.; Tininini, S.; Dewilde, S.; Strobl, B.; Fu, X.; Murray-Tait, V.; Chiarle, R.; Poli, V. The STAT3 isoforms α and β have unique and specific functions. Nat. Immunol., 2004, 5(4), 401-409. [http://dx.doi.org/10.1038/ni1052]. [PMID: 15021879].
[30]
Ng, I.H.; Ng, D.C.; Jans, D.A.; Bogoyevitch, M.A. Selective STAT3-α or -β expression reveals spliceform-specific phosphorylation kinetics, nuclear retention and distinct gene expression outcomes. Biochem. J., 2012, 447(1), 125-136. [http://dx.doi.org/10.1042/BJ20120941]. [PMID: 22799634].
[31]
Schaefer, T.S.; Sanders, L.K.; Park, O.K.; Nathans, D. Functional differences between Stat3alpha and Stat3beta. Mol. Cell. Biol., 1997, 17(9), 5307-5316. [http://dx.doi.org/10.1128/MCB.17.9.5307]. [PMID: 9271408].
[32]
Park, O.K.; Schaefer, L.K.; Wang, W.; Schaefer, T.S. Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms. J. Biol. Chem., 2000, 275(41), 32244-32249. [http://dx.doi.org/10.1074/jbc.M005082200]. [PMID: 10915797].
[33]
Yoo, J.Y.; Huso, D.L.; Nathans, D.; Desiderio, S. Specific ablation of Stat3beta distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell, 2002, 108(3), 331-344. [http://dx.doi.org/10.1016/S0092-8674(02)00636-0]. [PMID: 11853668].
[34]
Alonzi, T.; Maritano, D.; Gorgoni, B.; Rizzuto, G.; Libert, C.; Poli, V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene activation in the liver. Mol. Cell. Biol., 2001, 21(5), 1621-1632. [http://dx.doi.org/10.1128/MCB.21.5.1621-1632.2001]. [PMID: 11238899].
[35]
Levy, D.E.; Darnell, J.E. Stats: Transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol., 2002, 3(9), 651-662. [http://dx.doi.org/10.1038/nrm909]. [PMID: 12209125].
[36]
Furqan, M.; Akinleye, A.; Mukhi, N.; Mittal, V.; Chen, Y.; Liu, D. STAT inhibitors for cancer therapy. J. Hematol. Oncol., 2013, 6(1), 90. [http://dx.doi.org/10.1186/1756-8722-6-90]. [PMID: 24308725].
[37]
Darnell, J.E.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994, 264(5164), 1415-1421. [http://dx.doi.org/10.1126/science.8197455]. [PMID: 8197455].
[38]
Zhong, Z.; Wen, Z.; Darnell, J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science, 1994, 264(5155), 95-98. [http://dx.doi.org/10.1126/science.8140422]. [PMID: 8140422].
[39]
Khatib, H.; Huang, W.; Mikheil, D.; Schutzkus, V.; Monson, R.L. Effects of signal transducer and activator of transcription (STAT) genes STAT1 and STAT3 genotypic combinations on fertilization and embryonic survival rates in Holstein cattle. J. Dairy Sci., 2009, 92(12), 6186-6191. [http://dx.doi.org/10.3168/jds.2009-2439]. [PMID: 19923622].
[40]
Decker, T.; Kovarik, P. Transcription factor activity of STAT proteins: Structural requirements and regulation by phosphorylation and interacting proteins. Cell. Mol. Life Sci., 1999, 55(12), 1535-1546. [http://dx.doi.org/10.1007/s000180050393]. [PMID: 10526571].
[41]
Gupta, M.; Han, J.J.; Stenson, M.; Maurer, M.; Wellik, L.; Hu, G.; Ziesmer, S.; Dogan, A.; Witzig, T.E. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: A mechanism of aberrant JAK2 activation. Blood, 2012, 119(12), 2844-2853. [http://dx.doi.org/10.1182/blood-2011-10-388538]. [PMID: 22323454].
[42]
Ernst, M.; Najdovska, M.; Grail, D.; Lundgren-May, T.; Buchert, M.; Tye, H.; Matthews, V.B.; Armes, J.; Bhathal, P.S.; Hughes, N.R.; Marcusson, E.G.; Karras, J.G.; Na, S.; Sedgwick, J.D.; Hertzog, P.J.; Jenkins, B.J. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest., 2008, 118(5), 1727-1738. [http://dx.doi.org/10.1172/JCI34944]. [PMID: 18431520].
[43]
Kunisada, K.; Hirota, H.; Fujio, Y.; Matsui, H.; Tani, Y.; Yamauchi-Takihara, K.; Kishimoto, T. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation, 1996, 94(10), 2626-2632. [http://dx.doi.org/10.1161/01.CIR.94.10.2626]. [PMID: 8921810].
[44]
Zhao, D.; Pan, C.; Sun, J.; Gilbert, C.; Drews-Elger, K.; Azzam, D.J.; Picon-Ruiz, M.; Kim, M.; Ullmer, W.; El-Ashry, D.; Creighton, C.J.; Slingerland, J.M. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene, 2015, 34(24), 3107-3119. [http://dx.doi.org/10.1038/onc.2014.257]. [PMID: 25151964].
[45]
Wang, Y.; van Boxel-Dezaire, A.H.; Cheon, H.; Yang, J.; Stark, G.R. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc. Natl. Acad. Sci. USA, 2013, 110(42), 16975-16980. [http://dx.doi.org/10.1073/pnas.1315862110]. [PMID: 24082147].
[46]
Zong, C.S.; Chan, J.; Levy, D.E.; Horvath, C.; Sadowski, H.B.; Wang, L.H. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J. Biol. Chem., 2000, 275(20), 15099-15105. [http://dx.doi.org/10.1074/jbc.M000089200]. [PMID: 10747872].
[47]
Vignais, M.L.; Sadowski, H.B.; Watling, D.; Rogers, N.C.; Gilman, M. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol. Cell. Biol., 1996, 16(4), 1759-1769. [http://dx.doi.org/10.1128/MCB.16.4.1759]. [PMID: 8657151].
[48]
Coppo, P.; Flamant, S.; De Mas, V.; Jarrier, P.; Guillier, M.; Bonnet, M.L.; Lacout, C.; Guilhot, F.; Vainchenker, W.; Turhan, A.G. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br. J. Haematol., 2006, 134(2), 171-179. [http://dx.doi.org/10.1111/j.1365-2141.2006.06161.x]. [PMID: 16846476].
[49]
Schreiner, S.J. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J. Biol. Chem., 2002, 277(47), 45680-45687. [DOI: 10.1074/jbc.M204255200].
[50]
Eyking, A.; Ey, B.; Rünzi, M.; Roig, A.I.; Reis, H.; Schmid, K.W.; Gerken, G.; Podolsky, D.K.; Cario, E. Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology, 2011, 141(6), 2154-2165. [http://dx.doi.org/10.1053/j.gastro.2011.08.043]. [PMID: 21920464].
[51]
Lee, H.; Deng, J.; Kujawski, M.; Yang, C.; Liu, Y.; Herrmann, A.; Kortylewski, M.; Horne, D.; Somlo, G.; Forman, S.; Jove, R.; Yu, H. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med., 2010, 16(12), 1421-1428. [http://dx.doi.org/10.1038/nm.2250]. [PMID: 21102457].
[52]
Chung, J.; Uchida, E.; Grammer, T.C.; Blenis, J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol., 1997, 17(11), 6508-6516. [http://dx.doi.org/10.1128/MCB.17.11.6508]. [PMID: 9343414].
[53]
Lim, C.P.; Cao, X. Serine phosphorylation and negative regulation of Stat3 by JNK. J. Biol. Chem., 1999, 274(43), 31055-31061. [http://dx.doi.org/10.1074/jbc.274.43.31055]. [PMID: 10521505].
[54]
Jain, N.; Zhang, T.; Kee, W.H.; Li, W.; Cao, X. Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. J. Biol. Chem., 1999, 274(34), 24392-24400. [http://dx.doi.org/10.1074/jbc.274.34.24392]. [PMID: 10446219].
[55]
Androutsellis-Theotokis, A.; Leker, R.R.; Soldner, F.; Hoeppner, D.J.; Ravin, R.; Poser, S.W.; Rueger, M.A.; Bae, S.K.; Kittappa, R.; McKay, R.D. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature, 2006, 442(7104), 823-826. [http://dx.doi.org/10.1038/nature04940]. [PMID: 16799564].
[56]
Liu, H.; Ma, Y.; Cole, S.M.; Zander, C.; Chen, K.H.; Karras, J.; Pope, R.M. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood, 2003, 102(1), 344-352. [http://dx.doi.org/10.1182/blood-2002-11-3396]. [PMID: 12637318].
[57]
Wegrzyn, J.; Potla, R.; Chwae, Y.J.; Zhang, Q.; Derecka, M.; Szczepanek, K. Szelag1, M.;Gornicka, A.;Moh, A.;Moghaddas, S.; Chen, Q.; Bobbili, S.;Fu, X.Y.; Lesnefsky, E.J. 372 A novel function of STAT3 in cellular respiration. Cytokine, 2008, 43(3), 331-331. [http://dx.doi.org/10.1016/j.cyto.2008.07.457].
[58]
Gough, D.J.; Corlett, A.; Schlessinger, K.; Wegrzyn, J.; Larner, A.C.; Levy, D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science, 2009, 324(5935), 1713-1716. [http://dx.doi.org/10.1126/science.1171721]. [PMID: 19556508].
[59]
Butturini, E.; Gotte, G.; Dell’Orco, D.; Chiavegato, G.; Marino, V.; Canetti, D.; Cozzolino, F.; Monti, M.; Pucci, P.; Mariotto, S. Intermolecular disulfide bond influences unphosphorylated STAT3 dimerization and function. Biochem. J., 2016, 473(19), 3205-3219. [http://dx.doi.org/10.1042/BCJ20160294]. [PMID: 27486258].
[60]
Yang, J.; Chatterjee-Kishore, M.; Staugaitis, S.M.; Nguyen, H.; Schlessinger, K.; Levy, D.E.; Stark, G.R. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res., 2005, 65(3), 939-947. [PMID: 15705894].
[61]
Yang, J.; Liao, X.; Agarwal, M.K.; Barnes, L.; Auron, P.E.; Stark, G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev., 2007, 21(11), 1396-1408. [http://dx.doi.org/10.1101/gad.1553707]. [PMID: 17510282].
[62]
Yuan, Z.L.; Guan, Y.J.; Chatterjee, D.; Chin, Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science, 2005, 307(5707), 269-273. [http://dx.doi.org/10.1126/science.1105166]. [PMID: 15653507].
[63]
Zhang, Y.; Wang, D.; Xu, J.; Wang, Y.; Ma, F.; Li, Z.; Liu, N. Stat3 activation is critical for pluripotency maintenance. J. Cell. Physiol., 2019, 234(2), 1044-1051. [http://dx.doi.org/10.1002/jcp.27241]. [PMID: 30256396].
[64]
Aaronson, D.S.; Horvath, C.M. A road map for those who don’t know JAK-STAT. Science, 2002, 296(5573), 1653-1655. [http://dx.doi.org/10.1126/science.1071545]. [PMID: 12040185].
[65]
Johnson, D.E.; O’Keefe, R.A.; Grandis, J.R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol., 2018, 15(4), 234-248. [http://dx.doi.org/10.1038/nrclinonc.2018.8]. [PMID: 29405201].
[66]
Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer, 2009, 9(11), 798-809. [http://dx.doi.org/10.1038/nrc2734]. [PMID: 19851315].
[67]
Kortylewski, M.; Yu, H. Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol., 2008, 20(2), 228-233. [http://dx.doi.org/10.1016/j.coi.2008.03.010]. [PMID: 18479894].
[68]
Baek, S.H.; Ko, J.H.; Lee, H.; Jung, J.; Kong, M.; Lee, J.W.; Lee, J.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Lee, S.G.; Shim, B.S.; Sethi, G.; Kim, S.H.; Yang, W.M.; Um, J.Y.; Ahn, K.S. Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: Role in apoptosis induction and radiosensitization in head and neck tumor cells. Phytomedicine, 2016, 23(5), 566-577. [http://dx.doi.org/10.1016/j.phymed.2016.02.011]. [PMID: 27064016].
[69]
Herrmann, A.; Kortylewski, M.; Kujawski, M.; Zhang, C.; Reckamp, K.; Armstrong, B.; Wang, L.; Kowolik, C.; Deng, J.; Figlin, R.; Yu, H. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res., 2010, 70(19), 7455-7464. [http://dx.doi.org/10.1158/0008-5472.CAN-10-0736]. [PMID: 20841481].
[70]
Yang, C.L.; Liu, Y.Y.; Ma, Y.G.; Xue, Y.X.; Liu, D.G.; Ren, Y.; Liu, X.B.; Li, Y.; Li, Z. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One, 2012, 7(5), e37960. [http://dx.doi.org/10.1371/journal.pone.0037960]. [PMID: 22662257].
[71]
Vainchenker, W.; Constantinescu, S.N. JAK/STAT signaling in hematological malignancies. Oncogene, 2013, 32(21), 2601-2613. [http://dx.doi.org/10.1038/onc.2012.347]. [PMID: 22869151].
[72]
Couronné, L.; Scourzic, L.; Pilati, C.; Della Valle, V.; Duffourd, Y.; Solary, E.; Vainchenker, W.; Merlio, J.P.; Beylot-Barry, M.; Damm, F.; Stern, M.H.; Gaulard, P.; Lamant, L.; Delabesse, E.; Merle-Beral, H.; Nguyen-Khac, F.; Fontenay, M.; Tilly, H.; Bastard, C.; Zucman-Rossi, J.; Bernard, O.A.; Mercher, T. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica, 2013, 98(11), 1748-1752. [http://dx.doi.org/10.3324/haematol.2013.085068]. [PMID: 23872306].
[73]
Groner, B.; Von Manstein, V. Jak Stat signaling and targeted inhibition. Mol. Cell. Endocrinol., 2017, 451, 1-14. [http://dx.doi.org/10.1016/j.mce.2017.05.033]. [PMID: 28576744].
[74]
Duan, S.; Tsai, Y.; Keng, P.; Chen, Y.; Lee, S.O.; Chen, Y. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. Oncotarget, 2015, 6(29), 27651-27660. [http://dx.doi.org/10.18632/oncotarget.4753]. [PMID: 26313152].
[75]
Yang, C.H.; Chou, H.C.; Fu, Y.N.; Yeh, C.L.; Cheng, H.W.; Chang, I.C.; Liu, K.J.; Chang, G.C.; Tsai, T.F.; Tsai, S.F.; Liu, H.P.; Wu, Y.C.; Chen, Y.T.; Huang, S.F.; Chen, Y.R. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. Biochim. Biophys. Acta, 2015, 1852(7), 1540-1549. [http://dx.doi.org/10.1016/j.bbadis.2015.04.020]. [PMID: 25912735].
[76]
Harada, D.; Takigawa, N.; Kiura, K. The role of STAT3 in non-small cell lung cancer. Cancers (Basel), 2014, 6(2), 708-722. [http://dx.doi.org/10.3390/cancers6020708]. [PMID: 24675568].
[77]
He, G.; Yu, G.Y.; Temkin, V.; Ogata, H.; Kuntzen, C.; Sakurai, T.; Sieghart, W.; Peck-Radosavljevic, M.; Leffert, H.L.; Karin, M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell, 2010, 17(3), 286-297. [http://dx.doi.org/10.1016/j.ccr.2009.12.048]. [PMID: 20227042].
[78]
He, G.; Karin, M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res., 2011, 21(1), 159-168. [http://dx.doi.org/10.1038/cr.2010.183]. [PMID: 21187858].
[79]
Calvisi, D.F.; Ladu, S.; Gorden, A.; Farina, M.; Conner, E.A.; Lee, J.S.; Factor, V.M.; Thorgeirsson, S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology, 2006, 130(4), 1117-1128. [http://dx.doi.org/10.1053/j.gastro.2006.01.006]. [PMID: 16618406].
[80]
Wu, W.Y.; Li, J.; Wu, Z.S.; Zhang, C.L.; Meng, X.L. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer, 2011, 11(1), 506-506. [http://dx.doi.org/10.1186/1471-2407-11-506]. [PMID: 22136659].
[81]
Park, J.H.; van Wyk, H.; McMillan, D.C.; Quinn, J.; Clark, J.; Roxburgh, C.S.; Horgan, P.G.; Edwards, J. Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host. Clin. Cancer Res., 2017, 23(7), 1698-1709. [http://dx.doi.org/10.1158/1078-0432.CCR-16-1416]. [PMID: 27678454].
[82]
Lin, L.; Liu, A.; Peng, Z.; Lin, H.J.; Li, P.K.; Li, C.; Lin, J. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res., 2011, 71(23), 7226-7237. [http://dx.doi.org/10.1158/0008-5472.CAN-10-4660]. [PMID: 21900397].
[83]
Chai, E.Z.P.; Shanmugam, M.K.; Arfuso, F.; Dharmarajan, A.; Wang, C.; Kumar, A.P.; Samy, R.P.; Lim, L.H.K.; Wang, L.; Goh, B.C.; Ahn, K.S.; Hui, K.M.; Sethi, G. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol. Ther., 2016, 162, 86-97. [http://dx.doi.org/10.1016/j.pharmthera.2015.10.004]. [PMID: 26478441].
[84]
Kim, J.E.; Patel, M.; Ruzevick, J.; Jackson, C.M.; Lim, M. STAT3 Activation in Glioblastoma: Biochemical and therapeutic implications. Cancers (Basel), 2014, 6(1), 376-395. [http://dx.doi.org/10.3390/cancers6010376]. [PMID: 24518612].
[85]
Akira, S.; Nishio, Y.; Inoue, M.; Wang, X.J.; Wei, S.; Matsusaka, T.; Yoshida, K.; Sudo, T.; Naruto, M.; Kishimoto, T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell, 1994, 77(1), 63-71. [http://dx.doi.org/10.1016/0092-8674(94)90235-6]. [PMID: 7512451].
[86]
Mackey-Lawrence, N.M.; Petri, W.A., Jr Leptin and mucosal immunity. Mucosal Immunol., 2012, 5(5), 472-479. [http://dx.doi.org/10.1038/mi.2012.40]. [PMID: 22692456].
[87]
Sehgal, P.B. Paradigm shifts in the cell biology of STAT signaling. Semin. Cell Dev. Biol., 2008, 19(4), 329-340. [http://dx.doi.org/10.1016/j.semcdb.2008.07.003]. [PMID: 18691663].
[88]
Roca Suarez, A.A.; Van Renne, N.; Baumert, T.F.; Lupberger, J. Viral manipulation of STAT3: Evade, exploit, and injure. PLoS Pathog., 2018, 14(3), e1006839. [http://dx.doi.org/10.1371/journal.ppat.1006839]. [PMID: 29543893].
[89]
Liu, F.; Poursine-Laurent, J.; Wu, H.Y.; Link, D.C. Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. Blood, 1997, 90(7), 2583-2590. [PMID: 9326224].
[90]
Rochman, I.; Paul, W.E.; Ben-Sasson, S.Z. IL-6 increases primed cell expansion and survival. J. Immunol., 2005, 174(8), 4761-4767. [http://dx.doi.org/10.4049/jimmunol.174.8.4761]. [PMID: 15814701].
[91]
Yu, C.R.; Dambuza, I.M.; Lee, Y.J.; Frank, G.M.; Egwuagu, C.E. STAT3 regulates proliferation and survival of CD8+ T cells: enhances effector responses to HSV-1 infection, and inhibits IL-10+ regulatory CD8+ T cells in autoimmune uveitis. Mediators Inflamm., 2013, 2013, 359674. [http://dx.doi.org/10.1155/2013/359674]. [PMID: 24204098].
[92]
Ivanov, I.I.; McKenzie, B.S.; Zhou, L.; Tadokoro, C.E.; Lepelley, A.; Lafaille, J.J.; Cua, D.J.; Littman, D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell, 2006, 126(6), 1121-1133. [http://dx.doi.org/10.1016/j.cell.2006.07.035]. [PMID: 16990136].
[93]
Korn, T.; Mitsdoerffer, M.; Croxford, A.L.; Awasthi, A.; Dardalhon, V.A.; Galileos, G.; Vollmar, P.; Stritesky, G.L.; Kaplan, M.H.; Waisman, A.; Kuchroo, V.K.; Oukka, M. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA, 2008, 105(47), 18460-18465. [http://dx.doi.org/10.1073/pnas.0809850105]. [PMID: 19015529].
[94]
Nowell, M.A.; Williams, A.S.; Carty, S.A.; Scheller, J.; Hayes, A.J.; Jones, G.W.; Richards, P.J.; Slinn, S.; Ernst, M.; Jenkins, B.J.; Topley, N.; Rose-John, S.; Jones, S.A. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol., 2009, 182(1), 613-622. [http://dx.doi.org/10.4049/jimmunol.182.1.613]. [PMID: 19109195].
[95]
Ma, C.S.; Avery, D.T.; Chan, A.; Batten, M.; Bustamante, J.; Boisson-Dupuis, S.; Arkwright, P.D.; Kreins, A.Y.; Averbuch, D.; Engelhard, D.; Magdorf, K.; Kilic, S.S.; Minegishi, Y.; Nonoyama, S.; French, M.A.; Choo, S.; Smart, J.M.; Peake, J.; Wong, M.; Gray, P.; Cook, M.C.; Fulcher, D.A.; Casanova, J.L.; Deenick, E.K.; Tangye, S.G. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood, 2012, 119(17), 3997-4008. [http://dx.doi.org/10.1182/blood-2011-11-392985]. [PMID: 22403255].
[96]
Eto, D.; Lao, C.; DiToro, D.; Barnett, B.; Escobar, T.C.; Kageyama, R.; Yusuf, I.; Crotty, S. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS One, 2011, 6(3), e17739. [http://dx.doi.org/10.1371/journal.pone.0017739]. [PMID: 21423809].
[97]
Ma, C.S.; Deenick, E.K.; Batten, M.; Tangye, S.G. The origins, function, and regulation of T follicular helper cells. J. Exp. Med., 2012, 209(7), 1241-1253. [http://dx.doi.org/10.1084/jem.20120994]. [PMID: 22753927].
[98]
Ouyang, W.; Rutz, S.; Crellin, N.K.; Valdez, P.A.; Hymowitz, S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol., 2011, 29(29), 71-109. [http://dx.doi.org/10.1146/annurev-immunol-031210-101312]. [PMID: 21166540].
[99]
Wu, C.; Orozco, C.; Boyer, J.; Leglise, M.; Goodale, J.; Batalov, S.; Hodge, C.L.; Haase, J.; Janes, J.; Huss, J.W., III; Su, A.I. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol., 2009, 10(11), R130. [http://dx.doi.org/10.1186/gb-2009-10-11-r130]. [PMID: 19919682].
[100]
Cavani, A.; Nasorri, F.; Prezzi, C.; Sebastiani, S.; Albanesi, C.; Girolomoni, G. Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J. Invest. Dermatol., 2000, 114(2), 295-302. [http://dx.doi.org/10.1046/j.1523-1747.2000.00881.x]. [PMID: 10651989].
[101]
Itoh, K.; Hirohata, S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J. Immunol., 1995, 154(9), 4341-4350. [PMID: 7722292].
[102]
Saito, M.; Nagasawa, M.; Takada, H.; Hara, T.; Tsuchiya, S.; Agematsu, K.; Yamada, M.; Kawamura, N.; Ariga, T.; Tsuge, I.; Nonoyama, S.; Karasuyama, H.; Minegishi, Y. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J. Exp. Med., 2011, 208(2), 235-249. [http://dx.doi.org/10.1084/jem.20100799]. [PMID: 21300911].
[103]
Yoshimura, A.; Naka, T.; Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol., 2007, 7(6), 454-465. [http://dx.doi.org/10.1038/nri2093]. [PMID: 17525754].
[104]
Yu, H.; Lee, H.; Herrmann, A.; Buettner, R.; Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer, 2014, 14(11), 736-746. [http://dx.doi.org/10.1038/nrc3818]. [PMID: 25342631].
[105]
Darnell, J.E. Validating Stat3 in cancer therapy. Nat. Med., 2005, 11(6), 595-596. [http://dx.doi.org/10.1038/nm0605-595]. [PMID: 15937466].
[106]
Resetca, D.; Haftchenary, S.; Gunning, P.T.; Wilson, D.J. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization. J. Biol. Chem., 2014, 289(47), 32538-32547. [http://dx.doi.org/10.1074/jbc.M114.595454]. [PMID: 25288792].
[107]
Shin, D.S.; Kim, H.N.; Shin, K.D.; Yoon, Y.J.; Kim, S.J.; Han, D.C.; Kwon, B.M. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res., 2009, 69(1), 193-202. [http://dx.doi.org/10.1158/0008-5472.CAN-08-2575]. [PMID: 19118003].
[108]
Timofeeva, O.A.; Gaponenko, V.; Lockett, S.J.; Tarasov, S.G.; Jiang, S.; Michejda, C.J.; Perantoni, A.O.; Tarasova, N.I. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem. Biol., 2007, 2(12), 799-809. [http://dx.doi.org/10.1021/cb700186x]. [PMID: 18154267].
[109]
Liu, L.; McBride, K.M.; Reich, N.C. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc. Natl. Acad. Sci. USA, 2005, 102(23), 8150-8155. [http://dx.doi.org/10.1073/pnas.0501643102]. [PMID: 15919823].
[110]
Nkansah, E.; Shah, R.; Collie, G.W.; Parkinson, G.N.; Palmer, J.; Rahman, K.M.; Bui, T.T.; Drake, A.F.; Husby, J.; Neidle, S.; Zinzalla, G.; Thurston, D.E.; Wilderspin, A.F. Observation of unphosphorylated STAT3 core protein binding to target dsDNA by PEMSA and X-ray crystallography. FEBS Lett., 2013, 587(7), 833-839. [http://dx.doi.org/10.1016/j.febslet.2013.01.065]. [PMID: 23434585].
[111]
Beebe, J.D.; Liu, J.Y.; Zhang, J.T. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharmacol. Ther., 2018, 191, 74-91. [http://dx.doi.org/10.1016/j.pharmthera.2018.06.006]. [PMID: 29933035].
[112]
Song, H.; Wang, R.; Wang, S.; Lin, J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA, 2005, 102(13), 4700-4705. [http://dx.doi.org/10.1073/pnas.0409894102]. [PMID: 15781862].
[113]
Chen, C.L.; Loy, A.; Cen, L.; Chan, C.; Hsieh, F.C.; Cheng, G.; Wu, B.; Qualman, S.J.; Kunisada, K.; Yamauchi-Takihara, K.; Lin, J. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer, 2007, 7(1), 111. [http://dx.doi.org/10.1186/1471-2407-7-111]. [PMID: 17598902].
[114]
Miyoshi, K.; Takaishi, M.; Nakajima, K.; Ikeda, M.; Kanda, T.; Tarutani, M.; Iiyama, T.; Asao, N.; DiGiovanni, J.; Sano, S. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J. Invest. Dermatol., 2011, 131(1), 108-117. [http://dx.doi.org/10.1038/jid.2010.255]. [PMID: 20811392].
[115]
Nadeem, A.; Al-Harbi, N.O.; Ansari, M.A.; Al-Harbi, M.M.; El-Sherbeeny, A.M.; Zoheir, K.M.A.; Attia, S.M.; Hafez, M.M.; Al-Shabanah, O.A.; Ahmad, S.F. Psoriatic inflammation enhances allergic airway inflammation through IL-23/STAT3 signaling in a murine model. Biochem. Pharmacol., 2017, 124, 69-82. [http://dx.doi.org/10.1016/j.bcp.2016.10.012]. [PMID: 27984001].
[116]
Bhasin, D.; Cisek, K.; Pandharkar, T.; Regan, N.; Li, C.; Pandit, B.; Lin, J.; Li, P.K. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(1), 391-395. [http://dx.doi.org/10.1016/j.bmcl.2007.10.031]. [PMID: 18006313].
[117]
Lin, L.; Hutzen, B.; Li, P.K.; Ball, S.; Zuo, M.; DeAngelis, S.; Foust, E.; Sobo, M.; Friedman, L.; Bhasin, D.; Cen, L.; Li, C.; Lin, J. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia, 2010, 12(1), 39-50. [http://dx.doi.org/10.1593/neo.91196]. [PMID: 20072652].
[118]
Ball, S.; Li, C.; Li, P.K.; Lin, J. The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One, 2011, 6(4), e18820. [http://dx.doi.org/10.1371/journal.pone.0018820]. [PMID: 21526200].
[119]
Lin, L.; Benson, D.M., Jr; DeAngelis, S.; Bakan, C.E.; Li, P.K.; Li, C.; Lin, J. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int. J. Cancer, 2012, 130(6), 1459-1469. [http://dx.doi.org/10.1002/ijc.26152]. [PMID: 21520044].
[120]
Wei, C.C.; Ball, S.; Lin, L.; Liu, A.; Fuchs, J.R.; Li, P.K.; Li, C.; Lin, J. Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells. Int. J. Oncol., 2011, 38(1), 279-285. [PMID: 21109950].
[121]
Onimoe, G.I.; Liu, A.; Lin, L.; Wei, C.C.; Schwartz, E.B.; Bhasin, D.; Li, C.; Fuchs, J.R.; Li, P.K.; Houghton, P.; Termuhlen, A.; Gross, T.; Lin, J. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest. New Drugs, 2012, 30(3), 916-926. [http://dx.doi.org/10.1007/s10637-011-9645-1]. [PMID: 21340507].
[122]
Jung, K.H.; Yoo, W.; Stevenson, H.L.; Deshpande, D.; Shen, H.; Gagea, M.; Yoo, S.Y.; Wang, J.; Eckols, T.K.; Bharadwaj, U.; Tweardy, D.J. Multi-functional effects of a small-molecule STAT3 inhibitor on NASH and HCC in mice. Clin. Cancer Res., 2017, 23(18), 5537-5546. [http://dx.doi.org/10.1158/1078-0432.CCR-16-2253]. [PMID: 28533225].
[123]
Schust, J.; Sperl, B.; Hollis, A.; Mayer, T.U.; Berg, T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol., 2006, 13(11), 1235-1242. [http://dx.doi.org/10.1016/j.chembiol.2006.09.018]. [PMID: 17114005].
[124]
Adachi, M.; Cui, C.; Dodge, C.T.; Bhayani, M.K.; Lai, S.Y. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol., 2012, 48(12), 1220-1226. [http://dx.doi.org/10.1016/j.oraloncology.2012.06.006]. [PMID: 22770899].
[125]
Villalva, C.; Martin-Lannerée, S.; Cortes, U.; Dkhissi, F.; Wager, M.; Le Corf, A.; Tourani, J.M.; Dusanter-Fourt, I.; Turhan, A.G.; Karayan-Tapon, L. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int. J. Cancer, 2011, 128(4), 826-838. [http://dx.doi.org/10.1002/ijc.25416]. [PMID: 20473906].
[126]
Chung, S.S.; Giehl, N.; Wu, Y.; Vadgama, J.V. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int. J. Oncol., 2014, 44(2), 403-411. [http://dx.doi.org/10.3892/ijo.2013.2195]. [PMID: 24297508].
[127]
Han, Z.; Wang, X.; Ma, L.; Chen, L.; Xiao, M.; Huang, L.; Cao, Y.; Bai, J.; Ma, D.; Zhou, J.; Hong, Z. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget, 2014, 5(18), 8416-8428. [http://dx.doi.org/10.18632/oncotarget.2314]. [PMID: 25261365].
[128]
Lin, L.; Hutzen, B.; Lee, H.F.; Peng, Z.; Wang, W.; Zhao, C.; Lin, H.J.; Sun, D.; Li, P.K.; Li, C.; Korkaya, H.; Wicha, M.S.; Lin, J. Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells. PLoS One, 2013, 8(12), e82821. [http://dx.doi.org/10.1371/journal.pone.0082821]. [PMID: 24376586].
[129]
Pan, Y.; Zhou, F.; Zhang, R.; Claret, F.X. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS One, 2013, 8(1), e54565. [http://dx.doi.org/10.1371/journal.pone.0054565]. [PMID: 23382914].
[130]
Matsuno, K.; Masuda, Y.; Uehara, Y.; Sato, H.; Muroya, A.; Takahashi, O.; Yokotagawa, T.; Furuya, T.; Okawara, T.; Otsuka, M.; Ogo, N.; Ashizawa, T.; Oshita, C.; Tai, S.; Ishii, H.; Akiyama, Y.; Asai, A. Identification of a new series of STAT3 inhibitors by virtual screening. ACS Med. Chem. Lett., 2010, 1(8), 371-375. [http://dx.doi.org/10.1021/ml1000273]. [PMID: 24900220].
[131]
Ashizawa, T.; Miyata, H.; Ishii, H.; Oshita, C.; Matsuno, K.; Masuda, Y.; Furuya, T.; Okawara, T.; Otsuka, M.; Ogo, N.; Asai, A.; Akiyama, Y. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int. J. Oncol., 2011, 38(5), 1245-1252. [PMID: 21369699].
[132]
Siddiquee, K.; Zhang, S.; Guida, W.C.; Blaskovich, M.A.; Greedy, B.; Lawrence, H.R.; Yip, M.L.; Jove, R.; McLaughlin, M.M.; Lawrence, N.J.; Sebti, S.M.; Turkson, J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. USA, 2007, 104(18), 7391-7396. [http://dx.doi.org/10.1073/pnas.0609757104]. [PMID: 17463090].
[133]
Bu, L.L.; Deng, W.W.; Huang, C.F.; Liu, B.; Zhang, W.F.; Sun, Z.J. Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma. Am. J. Cancer Res., 2015, 5(5), 1751-1761. [PMID: 26175943].
[134]
Chen, C.L.; Loy, A.; Cen, L.; Chan, C.; Hsieh, F.C.; Cheng, G.; Wu, B.; Qualman, S.J.; Kunisada, K.; Yamauchi-Takihara, K.; Lin, J. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer, 2007, 7(1), 111. [http://dx.doi.org/10.1186/1471-2407-7-111]. [PMID: 17598902].
[135]
Bu, L.L.; Zhao, Z.L.; Liu, J.F.; Ma, S.R.; Huang, C.F.; Liu, B.; Zhang, W.F.; Sun, Z.J. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell. Oncotarget, 2015, 6(39), 41944-41958. [http://dx.doi.org/10.18632/oncotarget.5986]. [PMID: 26556875].
[136]
Kortylewski, M.; Yu, H. Stat3 as a potential target for cancer immunotherapy. J. Immunother., 2007, 30(2), 131-139. [http://dx.doi.org/10.1097/01.cji.0000211327.76266.65]. [PMID: 17471161].
[137]
Lin, L.; Amin, R.; Gallicano, G.I.; Glasgow, E.; Jogunoori, W.; Jessup, J.M.; Zasloff, M.; Marshall, J.L.; Shetty, K.; Johnson, L.; Mishra, L.; He, A.R. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene, 2009, 28(7), 961-972. [http://dx.doi.org/10.1038/onc.2008.448]. [PMID: 19137011].
[138]
Zhang, X.; Yue, P.; Fletcher, S.; Zhao, W.; Gunning, P.T.; Turkson, J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem. Pharmacol., 2010, 79(10), 1398-1409. [http://dx.doi.org/10.1016/j.bcp.2010.01.001]. [PMID: 20067773].
[139]
Fletcher, S.; Singh, J.; Zhang, X.; Yue, P.; Page, B.D.; Sharmeen, S.; Shahani, V.M.; Zhao, W.; Schimmer, A.D.; Turkson, J.; Gunning, P.T. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: Potent in vitro and tumor cell activities. ChemBioChem, 2009, 10(12), 1959-1964. [http://dx.doi.org/10.1002/cbic.200900172]. [PMID: 19644994].
[140]
Page, B.D.; Fletcher, S.; Yue, P.; Li, Z.; Zhang, X.; Sharmeen, S.; Datti, A.; Wrana, J.L.; Trudel, S.; Schimmer, A.D.; Turkson, J.; Gunning, P.T. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg. Med. Chem. Lett., 2011, 21(18), 5605-5609. [http://dx.doi.org/10.1016/j.bmcl.2011.06.056]. [PMID: 21788134].
[141]
Urlam, M.K.; Pireddu, R.; Ge, Y.; Zhang, X.; Sun, Y.; Lawrence, H.R.; Guida, W.C.; Sebti, S.M.; Lawrence, N.J. Development of new N-arylbenzamides as STAT3 dimerization inhibitors. MedChemComm, 2013, 4(6), 932-941. [http://dx.doi.org/10.1039/c3md20323a]. [PMID: 24073326].
[142]
Huang, W.; Dong, Z.; Wang, F.; Peng, H.; Liu, J.Y.; Zhang, J.T. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. ACS Chem. Biol., 2014, 9(5), 1188-1196. [http://dx.doi.org/10.1021/cb500071v]. [PMID: 24661007].
[143]
Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C.J.; Peng, H.; He, Y.; Hangoc, G.; Pollok, K.; Sandusky, G.; Fu, X.Y.; Broxmeyer, H.E.; Zhang, Z.Y.; Liu, J.Y.; Zhang, J.T. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene, 2016, 35(6), 802. [http://dx.doi.org/10.1038/onc.2015.419]. [PMID: 26865226].
[144]
Cafferkey, C.; Chau, I. Novel STAT 3 inhibitors for treating gastric cancer. Expert Opin. Investig. Drugs, 2016, 25(9), 1023-1031. [http://dx.doi.org/10.1080/13543784.2016.1195807]. [PMID: 27322026].
[145]
Ren, X.; Duan, L.; He, Q.; Zhang, Z.; Zhou, Y.; Wu, D.; Pan, J.; Pei, D.; Ding, K. Identification of Niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med. Chem. Lett., 2010, 1(9), 454-459. [http://dx.doi.org/10.1021/ml100146z]. [PMID: 24900231].
[146]
Chen, H.; Yang, Z.; Ding, C.; Chu, L.; Zhang, Y.; Terry, K.; Liu, H.; Shen, Q.; Zhou, J. Discovery of O-Alkylamino tethered niclosamide derivatives as potent and orally bioavailable anticancer agents. ACS Med. Chem. Lett., 2013, 4(2), 180-185. [http://dx.doi.org/10.1021/ml3003082]. [PMID: 23459613].
[147]
Chen, H.; Yang, Z.; Ding, C.; Chu, L.; Zhang, Y.; Terry, K.; Liu, H.; Shen, Q.; Zhou, J. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. [J] Eur. J. Med. Chem., 2013, 62, 498-507. [http://dx.doi.org/10.1016/j.ejmech.2013.01.023]. [PMID: 23416191].
[148]
Chen, H.; Yang, Z.; Ding, C.; Xiong, A.; Wild, C.; Wang, L.; Ye, N.; Cai, G.; Flores, R.M.; Ding, Y.; Shen, Q.; Zhou, J. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). Eur. J. Med. Chem., 2014, 82, 195-203. [http://dx.doi.org/10.1016/j.ejmech.2014.05.049]. [PMID: 24904966].
[149]
Shahani, V.M.; Yue, P.; Haftchenary, S.; Zhao, W.; Lukkarila, J.L.; Zhang, X.; Ball, D.; Nona, C.; Gunning, P.T.; Turkson, J. Identification of purine-scaffold small-molecule inhibitors of stat3 activation by QSAR studies. ACS Med. Chem. Lett., 2011, 2(1), 79-84. [http://dx.doi.org/10.1021/ml100224d]. [PMID: 21243039].
[150]
Yu, W.; Xiao, H.; Lin, J.; Li, C. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J. Med. Chem., 2013, 56(11), 4402-4412. [http://dx.doi.org/10.1021/jm400080c]. [PMID: 23651330].
[151]
Li, H.; Liu, A.; Zhao, Z.; Xu, Y.; Lin, J.; Jou, D.; Li, C. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). J. Med. Chem., 2011, 54(15), 5592-5596. [http://dx.doi.org/10.1021/jm101330h]. [PMID: 21678971].
Download PDF Flyer